Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Vasty Osei-Amponsa"'
Autor:
Xiuxiu Lu, Venkata R. Sabbasani, Vasty Osei-Amponsa, Christine N. Evans, Julianna C. King, Sergey G. Tarasov, Marzena Dyba, Sudipto Das, King C. Chan, Charles D. Schwieters, Sulbha Choudhari, Caroline Fromont, Yongmei Zhao, Bao Tran, Xiang Chen, Hiroshi Matsuo, Thorkell Andresson, Raj Chari, Rolf E. Swenson, Nadya I. Tarasova, Kylie J. Walters
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Rpn13 is a substrate receptor of the 26S proteasome and an anti-cancer drug target. Here, the authors identify and characterize XL5, a lead compound that binds to the N-terminal Pru domain of human Rpn13 (hRpn13), solve the NMR structure of XL5-ligat
Externí odkaz:
https://doaj.org/article/08204c7dee354ca7ab5e0c3b7e0c28d6
Autor:
Vasty Osei-Amponsa, Kylie J. Walters
Publikováno v:
Trends in biochemical sciences. 47(11)
The ubiquitin-proteasome system (UPS) is critical for protein quality control and regulating protein lifespans. Following ubiquitination, UPS substrates bind multidomain receptors that, in addition to ubiquitin-binding sites, contain functional domai
Autor:
Charles D. Schwieters, Xiuxiu Lu, Vasty Osei-Amponsa, Julianna C. King, Thorkell Andresson, Caroline Fromont, Rolf E. Swenson, Bao Tran, Xiang Chen, Kylie J. Walters, Yongmei Zhao, Nadya I. Tarasova, Hiroshi Matsuo, Marzena A. Dyba, Sulbha Choudhari, Raj Chari, Venkata R. Sabbasani, Sergey G. Tarasov, Christine N. Evans, King C. Chan
Proteasome substrate receptor hRpn13 is a promising anti-cancer target. By integrated in silico and biophysical screening, we identified a chemical scaffold that binds hRpn13 with non-covalent interactions that mimic the proteasome and a weak electro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb1579d6d5f0d3b01c43733af2d66184
https://doi.org/10.1101/2021.07.16.452547
https://doi.org/10.1101/2021.07.16.452547
Autor:
Justin B. Lack, Raj Chari, Mayank Tandon, Christine N. Evans, Kimberly D. Klarmann, Vinidhra Sridharan, Vasty Osei-Amponsa, Kwong Tai Cheng, Kylie J. Walters
Publikováno v:
Mol Cell Biol
hRpn13/ADRM1 links substrate recruitment with deubiquitination at the proteasome through its proteasome- and ubiquitin-binding Pru domain and DEUBAD domain, which binds and activates deubiquitinating enzyme (DUB) UCHL5/Uch37. Here, we edit the HCT116
Autor:
Hironobu Yamashita, Vonn Walter, Jenna M. Buckwalter, Zongyu Zheng, Klaus H. Kaestner, Chang Lu, David J. DeGraff, Justine Ellis, Xue-Ru Wu, Vasty Osei-Amponsa, Robert P. Feehan, Cathy Mendelsohn, Lisa M. Shantz, Hikmat Al-Ahmadie, Joshua I. Warrick, Lauren Shuman
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Advanced bladder cancer exhibits a unique degree of morphologic and molecular intratumoral heterogeneity. While tumor heterogeneity in bladder cancer is associated with ...
Autor:
Lauren Shuman, Jenna M. Buckwalter, Joshua I. Warrick, Vonn Walter, David J. DeGraff, Jay D. Raman, Xue-Ru Wu, Vasty Osei Amponsa
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Bladder cancer (BC) is the second most common urologic malignancy and has notable molecular and morphologic heterogeneity that is associated with clinical outcome. Trans...
Autor:
Robert P. Feehan, Jenna M. Buckwalter, Vonn Walter, Cathy Mendelsohn, Klaus H. Kaestner, Zongyu Zheng, Justine Ellis-Mohl, Lisa M. Shantz, Lauren Shuman, David J. DeGraff, Jay D. Raman, Vasty Osei-Amponsa, Thomas Wildermuth, Hironobu Yamashita, Chang Liu, Xue-Ru Wu, Hikmat Al-Ahmadie, Joshua I. Warrick
Publikováno v:
Oncogene. 39(6)
Intratumoral heterogeneity in bladder cancer is a barrier to accurate molecular sub-classification and treatment efficacy. However, individual cellular and mechanistic contributions to tumor heterogeneity are controversial. We examined potential mech
Autor:
Zongyu Zheng, Eunah Chung, Joo-Seop Park, Feng Yue, Wansong Guo, Wilson Chan, Joshua I. Warrick, Lauren Shuman, Vonn Walter, Vasty Osei Amponsa, David J. DeGraff, Jay D. Raman, Matthew Kaag, Tiffany L. Whitcomb, Tejaswi Iyyanki, Yuka Imamura Kawasawa, Hironobu Yamashita
Publikováno v:
Scientific Reports
Discrete bladder cancer molecular subtypes exhibit differential clinical aggressiveness and therapeutic response, which may have significant implications for identifying novel treatments for this common malignancy. However, research is hindered by th
Autor:
Hironobu Yamashita, Xue-Ru Wu, David J. DeGraff, Jay D. Raman, Zongyu Zheng, Vasty Osei Amponsa, Peter E. Clark, Joshua I. Warrick, Cathy Mendelsohn
Publikováno v:
Nature reviews. Urology. 14(2)
Genomic and transcriptional studies have identified discrete molecular subtypes of bladder cancer. These observations could be the starting point to identify new treatments. Several members of the forkhead box (FOX) superfamily of transcription facto
Autor:
Zongyu Zheng, Joshua I. Warrick, Hironobu Yamashita, Truc Tran, Wilson Chan, Vasty Osei Amponsa, David J. DeGraff, Jay D. Raman, Yuka Imamura
Publikováno v:
Journal of Urology. 195